How should kidney function be monitored during Ponatinib therapy?

Blood pressure at every visit and home monitoring; Vascular/cardiac symptom surveillance and ankle-brachial assessment when indicated; Lipids and glucose; Renal function during therapy.

How can kidney injury from Ponatinib be prevented?

Cardiovascular risk assessment and aggressive blood-pressure control Use the lowest effective dose; response-based dose reduction (PACE showed responses maintained after reduction)

Who is at higher risk of kidney injury from Ponatinib?

Pre-existing hypertension and cardiovascular disease; Higher ponatinib dose (45 mg vs reduced dosing); Older age and prior vascular events; Diabetes and other cardiometabolic risk factors.

Back to explorer

Printable monograph

BCR-ABL TKI

Ponatinib

Iclusig · PONA

BCR-ABL TKI · approved 2012 · 9 citations

Up to date· through 2025

Deeply sourced7/9 · 6 signals

Met: 9 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 10y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A third-generation BCR-ABL TKI potent against T315I, but carrying the highest vascular and hypertensive risk of the class.

ModerateBCR-ABL tyrosine kinase inhibitor

Chronic myeloid leukemia (T315I or resistant/intolerant)Philadelphia-positive acute lymphoblastic leukemia

§01

Signature kidney injury

Signature lesion

Hypertension

Ponatinib carries a black-box warning for arterial occlusive and thrombotic events and has the highest cardiovascular event rate among CML TKIs (about 41% in one comparative cohort; cumulative arterial occlusive events ~31% over 5 years in the PACE trial). Treatment-emergent hypertension is common; renal injury is largely a downstream consequence of hypertension and vascular disease.Source: Cortes et al., Blood 2018 (PACE 5-year); Madaudo et al., ESC Heart Fail 2025

Onset & rechallenge

Time to injuryVariable / unpredictable

Hypertension can emerge early while arterial occlusive events accrue over months, with dose reduction mitigating risk.

Distilled from: “Hypertension can emerge early; arterial occlusive events accrue over months, with dose reduction mitigating risk.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Hypertension#1 · Signature14.1%PMID 30892724 (opens PubMed in a new tab)
Hypertension reported in 14.1% of real-world ponatinib-treated CML (part of the arterial-occlusive toxicity profile)
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Thrombotic MicroangiopathyRarequalitative — no citable incidence
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityModerate

ReversibilityVariable

Evidence9 citations

Nephron map

GlomerulusFiltration barrier (podocytes + endothelium)

Vasculature / EndotheliumGlomerular & peritubular capillaries

Hypertension

Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.

§03

Kidney injury

Mechanism of kidney injury

Potent VEGFR and off-target kinase inhibition drives endothelial dysfunction, reduced nitric-oxide bioavailability, hypertension, and accelerated arterial occlusive disease. The kidney is affected mainly through systemic and renovascular hypertension and reduced renal perfusion rather than direct tubular toxicity; severe or accelerated hypertension can cause hypertension-mediated (and rarely thrombotic-microangiopathic) kidney injury.

Clinical presentation

New or worsening hypertension, arterial occlusive/ischemic events, and peripheral arterial disease; creatinine may rise with poorly controlled hypertension or vascular compromise. Severe hypertensive surges can produce a TMA-like picture.

Management

Treat hypertension promptly and to target; manage arterial events with cardiology/vascular input and consider dose reduction or interruption. Protecting the kidney centers on blood-pressure control and preserving renal perfusion; evaluate for TMA if MAHA accompanies a hypertensive crisis.Lesion-level management framework

Risk factors

Pre-existing hypertension and cardiovascular disease
Higher ponatinib dose (45 mg vs reduced dosing)
Older age and prior vascular events
Diabetes and other cardiometabolic risk factors

Prevention

Cardiovascular risk assessment and aggressive blood-pressure control
Use the lowest effective dose; response-based dose reduction (PACE showed responses maintained after reduction)

Anticancer mechanism· how it treats cancer

Third-generation pan-BCR-ABL1 inhibitor active against the T315I gatekeeper mutation, with broad multikinase activity including VEGFR, FGFR, and PDGFR. Used in resistant/intolerant CML and Ph+ ALL.

Note · Vascular toxicity and hypertension dominate; renal injury is a secondary, hypertension/perfusion-mediated effect rather than direct nephrotoxicity.

§04

Clinical depth

Renal dose adjustment

No specific renal dose adjustment is established (minimal renal excretion); dosing is driven instead by response and by mitigation of vascular toxicity (e.g., reduce to 15 mg on achieving response). Use caution in renal impairment given the vascular risk profile.

Dialyzability & ESKD dosing

Highly protein-bound and hepatically metabolized; not appreciably dialyzed and no supplemental dosing required in ESKD.

Differential diagnosis

Distinguish hypertension-mediated AKI and ischemic/atheroembolic injury from intrinsic nephrotoxicity (uncommon and mainly preclinical) and from ponatinib-associated TMA; the dominant driver is the vascular phenotype.

Monitoring

Blood pressure at every visit and home monitoring
Vascular/cardiac symptom surveillance and ankle-brachial assessment when indicated
Lipids and glucose
Renal function during therapy

Key trials & series

PACE (phase 2; 5-year arterial occlusive event and dose-reduction data)
Madaudo et al. comparative TKI cardiovascular cohort (highest CV event rate with ponatinib)

Clinical pearls

Ponatinib is the most vasculotoxic CML TKI - blood pressure control and the lowest effective dose are the renal protection strategy.
Response is often maintained after dose reduction, so de-escalation reduces arterial events without sacrificing efficacy.
Consider TMA if a hypertensive crisis is accompanied by hemolysis and thrombocytopenia.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the BCR-ABL TKI class.

Vascular

Hypertension, VTE/ATE, bleeding, aneurysm

Vascular occlusion (ponatinib), fluid retention

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Pleural effusions (dasatinib), PAH

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

QT, heart failure

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2015–2025 · 3 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedFocal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib.Arai H et al. · Intern Med 2023 · PMID 36642524First reported case of secondary focal segmental glomerulosclerosis with glomerular collapse, proteinuria, and renal function decline induced specifically by ponatinib (not by prior imatinib or nilotinib).CaseC · LimitedRenovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.Amin SO et al. · J Clin Hypertens (Greenwich) 2020 · PMID 32175644Case report of ponatinib-induced bilateral renal artery stenosis causing renovascular hypertension that responded to revascularization, directly matching the signature hypertension injury.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY See full prescribing information for complete boxed warning. Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG. ( 2.2 , 5.1 ) Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity. ( 2.2 , 5.2 ) Heart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure. ( 2.2 , 5.3 ) Hepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on…

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 5,180 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Hypertensioncorroborated · ROR 3.12 — on the terms that name the lesion (ROR 3.73)
Thrombotic Microangiopathycorroborated · ROR 2.62
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Hypertension

ROR 3.1295% CI 2.77–3.52· 286 reports

Thrombotic Microangiopathy

ROR 2.6295% CI 1.41–4.87· 10 reports

FAERS outcomes & reporting trend· 28.1% of reports w/ death · 32% w/ hospitalization

28.1%

Reported with a death outcome

1,453 of 5,180 reports

32%

Reported with hospitalization

1,659 of 5,180 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 5,180 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 1.2295% CI 0.92–1.64· 46 AKI reports ·no disproportionate AKI reporting signal (CI spans 1).

General / constitutional

Fatigue257Pyrexia254Chest Pain137Asthenia129Pain114

Gastrointestinal

Nausea194Constipation192Abdominal Pain160Diarrhoea133

Blood & lymphatic

Platelet Count Decreased166Thrombocytopenia146Neutropenia116Anaemia111

Skin

Rash271Dry Skin148

Musculoskeletal

Arthralgia165Pain In Extremity122

Nervous system

Headache267

Vascular

Hypertension194

Immune / infection

Pneumonia141

Respiratory

Dyspnoea123

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Ponatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Dinutuximab

Unituxin · Anti-GD2 antibody

Profile

Capillary-leak syndrome, hypertension and severe pain in neuroblastoma.

PREHTNTMA

Moderate#1 · 87% phenotype match

Asciminib

Scemblix · BCR-ABL STAMP inhibitor

Profile

Hypertension and pancreatitis; allosteric BCR-ABL inhibitor.

HTNPRE

Mild#2 · 76% phenotype match

Capecitabine

Xeloda · Pyrimidine analog (oral 5-FU)

Profile

Diarrhea-driven prerenal AKI; dose-adjust for CrCl.

PRETMA

Mild#3 · 68% phenotype match

5-Fluorouracil

Adrucil · Pyrimidine analog

Profile

Rare TMA, esp. with mitomycin; mostly renally safe.

TMAPRE

Mild#4 · 68% phenotype match

Trastuzumab emtansine (T-DM1)

Kadcyla · Antibody-drug conjugate (HER2/DM1)

Profile

Rare nodular regenerative TMA-like signals.

TMAGLOMHTN

Moderate#5 · 65% phenotype match

Sunitinib

Sutent · VEGFR TKI

Profile

VEGFR-TKI; hypertension and proteinuria, TMA reported.

HTNGLOMTMA

Moderate#6 · 64% phenotype match

Compare Ponatinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across BCR-ABL inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1NilotinibPRE — Prerenal / Hemodynamic AKIMild
2AsciminibHTN — HypertensionMild
3BosutinibPSEUDO — Pseudo-AKIMild
4ImatinibLYTE — Electrolyte DisturbanceMild
5OlverembatinibGLOM — Glomerular Injury / ProteinuriaMild
6Ponatinib· this agentHTN — HypertensionModerate
7DasatinibGLOM — Glomerular Injury / ProteinuriaFAERS AKIModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.